Ausgabe 3/2012
Inhalt (8 Artikel)
Apixaban: an Oral Direct Factor-Xa Inhibitor
David Jiménez, Roger D. Yusen, Eduardo Ramacciotti
Sunitinib: the First to Arrive at First-Line Metastatic Renal Cell Carcinoma
Sergio Vázquez, Luis León, Ovidio Fernández, Martín Lázaro, Enrique Grande, Luis Aparicio
Dipeptidyl Peptidase-4 Inhibitors in the Elderly: More Benefits or Risks?
Giuseppe Paolisso, Matteo Monami, Raffaele Marfella, Maria Rosaria Rizzo, Edoardo Mannucci
Cost per Treated Patient for Etanercept, Adalimumab, and Infliximab Across Adult Indications: a Claims Analysis
Machaon M. K. Bonafede, Shravanthi R. Gandra, Crystal Watson, Nicole Princic, Kathleen M. Fox
Exploring Channeling Optimized Radiofrequency Energy: a Review of Radiofrequency History and Applications in Esthetic Fields
Inna Belenky, Ariel Margulis, Monica Elman, Udi Bar-Yosef, Silviu D. Paun
Contribution of Endermology to Improving Indurations and Panniculitis/Lipoatrophy at Glatiramer Acetate Injection Site
Delia Rubio Fernández, Clara Rodríguez del Canto, Virginia Marcos Galán, Natalia Falcón, Héctor Edreira, Lidia Sevane Fernández, Pablo Francoli Martínez, Rainel Sánchez-De la Rosa
Uric Acid is an Important Predictor for Hypertensive Early Atherosclerosis
Ruya Mutluay, Serpil Muge Deger, Eylem Bahadir, Alim Ozgur Durmaz, Riza Çitil, Sukru Sindel
Phase 2 Study of Modified Irinotecan and Bolus 5-Fluorouracil/l-Leucovorin in Japanese Metastatic Colorectal Cancer Patients
Eishi Baba, Hiromitsu Fujishima, Akitaka Makiyama, Keita Uchino, Risa Tanaka, Taito Esaki, Hitoshi Kusaba, Kenji Mitsugi, Shuji Nakano, Koichi Akashi